申请人:Astellas Pharma Inc.
公开号:EP2305641A1
公开(公告)日:2011-04-06
[Object] A compound which is useful as an EP1 receptor antagonist is provided.
[Means for Solution] The present inventors investigated EP1 receptor antagonists, and confirmed that a compound having a sulfonamide structure, in which the nitrogen atom of the sulfonamide structure is substituted with 2-fluoropropyl group, 3-fluoro-2-methylpropyl group or the like, has a potent EP1 receptor antagonistic action, thereby completing the present invention. The sulfonamide compound of the present invention has a potent EP 1 receptor antagonistic action and can be used as an agent for preventing and/or treating a lower urinary tract symptom or the like.
[目的]本发明提供了一种可作为 EP1 受体拮抗剂的化合物。
[解决方法]本发明者对 EP1 受体拮抗剂进行了研究,确认了一种具有磺酰胺结构的化合物,其中磺酰胺结构的氮原子被 2-氟丙基、3-氟-2-甲基丙基或类似基团取代,具有强效的 EP1 受体拮抗作用,从而完成了本发明。本发明的磺酰胺化合物具有强效的 EP1 受体拮抗作用,可用作预防和/或治疗下尿路症状或类似症状的制剂。